Factor Xa Reagent Composition for Slower Anticoagulant Detection

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing methods for detecting and measuring factor Xa inhibitors in test samples are limited by rapid coagulation rates, which can lead to inaccurate or incomplete detection, especially when using high volumes or concentrations of factor Xa.

Innovation Solution

The use of factor Xa reagents containing guanidine derivatives, such as alkylated guanidines, which modulate factor Xa activity, allowing for slower reaction rates and enabling accurate detection of factor Xa inhibitors by extending the reaction time and allowing for higher sample volumes and concentrations of factor Xa to be used.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If high volumes or concentrations of factor Xa are used in the detection method, then the sensitivity of detection is improved, but the coagulation rate becomes too rapid leading to inaccurate or incomplete detection

Engineering Contradiction:
Improvedetection accuracyVSAvoidcoagulation rate
Core Design Contradiction:
Measurement precisionVSSpeed

Solution Approach 1:

The patent changes the chemical composition parameters of the reaction system by introducing guanidine derivatives (such as arginine, homocitrulline, or their salts) to modify the coagulation kinetics. These additives alter the reaction environment to slow down the coagulation rate, enabling accurate measurement even when high concentrations of factor Xa are used to improve detection sensitivity.

Inventive Principle:
Principle #35Parameter changes

2Measurement precision

If high volumes or concentrations of factor Xa are used to improve detection sensitivity, then measurement precision is improved, but the reaction time becomes too short for complete detection

Engineering Contradiction:
Improvedetection sensitivityVSAvoidreaction time
Core Design Contradiction:
Measurement precisionVSDuration of action of moving object

Solution Approach 1:

By modifying the reaction environment with guanidine derivatives, the patent extends the effective reaction time window. This allows the system to maintain high factor Xa concentrations for improved sensitivity while the modified kinetics provide sufficient time for complete detection before the coagulation process terminates the reaction.

Inventive Principle:
Principle #35Parameter changes

3Productivity

If the coagulation process proceeds rapidly, then productivity is improved, but measurement precision deteriorates due to inaccurate or incomplete detection

Engineering Contradiction:
Improvecoagulation speedVSAvoiddetection accuracy
Core Design Contradiction:
ProductivityVSMeasurement precision

Solution Approach 1:

The patent optimizes the reaction conditions by incorporating guanidine derivatives that moderate the coagulation kinetics. This creates an ideal balance where the reaction proceeds efficiently with good productivity while maintaining measurement precision through extended reaction time and reduced coagulation rate, enabling accurate detection of factor Xa inhibitors.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enables more precise and accurate detection of factor Xa inhibitors by slowing down the coagulation process, facilitating the use of greater test sample volumes and concentrations, thereby improving the sensitivity and reliability of detection methods.

Implementation Method 1

one or more of guanidine derivatives... The composition may modulate the activity of the factor Xa in the sample, where modulation comprises reducing a rate of coagulation or substrate cleavage caused by factor Xa

Methodology Applied
Scientific EffectEnzyme inhibition: Enzyme

Data Source

PatentEP4667582A1Factor xa reagent
Publication Date: 2025.12.24 INSTRUMENTATION LABORATORY COMPANY
  • EP4667582A1 patent drawingFigure 1A~1C
  • EP4667582A1 patent drawingFigure 1D~1F
  • EP4667582A1 patent drawingFigure 1G

AI summary

An example composition includes factor Xa, a substrate, one or more of guanidine derivatives, and, in some cases, heparin. An example method for detecting an anticoagulant in a sample includes combining or contacting the sample with the composition and measuring activity of the factor Xa based on a state of the substrate. The composition modulates the activity of the factor Xa in the sample, where modulation includes reducing a rate of coagulation of the sample caused by factor Xa. A presence of the anticoagulant is based on the activity of the factor Xa.